


Searching News Database: steatohepatitis
HSMN NewsFeed - 11 Jun 2026
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
HSMN NewsFeed - 25 Jun 2025
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
HSMN NewsFeed - 6 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
HSMN NewsFeed - 18 Jan 2023
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
HSMN NewsFeed - 10 Nov 2022
Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M
Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M
HSMN NewsFeed - 25 Aug 2022
HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
HSMN NewsFeed - 14 Dec 2021
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
HSMN NewsFeed - 27 May 2020
Acquist Therapeutics Announces New Appointments to its Board of Directors
Acquist Therapeutics Announces New Appointments to its Board of Directors
HSMN NewsFeed - 3 Mar 2020
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 19 Jun 2019
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
HSMN NewsFeed - 23 Apr 2019
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
HSMN NewsFeed - 28 Jan 2019
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
HSMN NewsFeed - 25 Oct 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
HSMN NewsFeed - 11 Sep 2018
Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
HSMN NewsFeed - 8 May 2018
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
HSMN NewsFeed - 7 Dec 2017
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
HSMN NewsFeed - 4 Dec 2017
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
HSMN NewsFeed - 30 Nov 2017
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
HSMN NewsFeed - 24 Oct 2017
Sequana Medical Announces Results of the MOSAIC Trial Data Presented at 2017 AASLD
Sequana Medical Announces Results of the MOSAIC Trial Data Presented at 2017 AASLD
HSMN NewsFeed - 20 Sep 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
HSMN NewsFeed - 18 Apr 2017
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
HSMN NewsFeed - 31 Aug 2015
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
HSMN NewsFeed - 27 May 2015
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Appoints Kathlene L. Powell Vice President, Quality Operations
Raptor Pharmaceutical Appoints Kathlene L. Powell Vice President, Quality Operations
HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
HSMN NewsFeed - 28 Jul 2009
Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
HSMN NewsFeed - 13 Apr 2009
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
HSMN NewsFeed - 11 Aug 2008
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
HSMN NewsFeed - 9 Jun 2008
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
HSMN NewsFeed - 5 Jun 2007
Enzo Life Sciences, Inc., Completes Acquisition of Axxora Life Sciences, Inc.
Enzo Life Sciences, Inc., Completes Acquisition of Axxora Life Sciences, Inc.
HSMN NewsFeed - 3 May 2007
Enzo Biochem Announces Supply and Royalty Bearing Cross-Licensing Agreements with Abbott
Enzo Biochem Announces Supply and Royalty Bearing Cross-Licensing Agreements with Abbott
Additional items found! 3
Members Archive contains
3 additional stories matching:
steatohepatitis
(Password required)
steatohepatitis
(Password required)
